| Bioactivity | Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3]. | ||||||||||||
| Invitro | Sertindole (0-100 μM; 48 h) attenuates proliferation of breast cancer cells[2].Sertindole (0.8-27.6 μM; 48 h) inhibits proliferation toward many cancers in vitro[2].Sertindole (5 μΜ and 10 μΜ; 24 h) attenuates migration of breast cancer cells[2]. Cell Proliferation Assay[2] Cell Line: | ||||||||||||
| In Vivo | Sertindole (oral gavage; 10 mg/kg; once daily; 12 d) shows anti-tumor activity in vivo[2]. Animal Model: | ||||||||||||
| Name | Sertindole | ||||||||||||
| CAS | 106516-24-9 | ||||||||||||
| Formula | C24H26ClFN4O | ||||||||||||
| Molar Mass | 440.94 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. David Murdoch, et al. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. [2]. Wei Zhang, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018 Oct 25;8(1):15753. [3]. Mario F Juruena, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85. |
Sertindole
CAS: 106516-24-9 F: C24H26ClFN4O W: 440.94
Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.